What are the recommended diagnostic and surveillance strategies for individuals suspected of having Lynch syndrome?

Lynch Syndrome: Diagnostic and Surveillance Strategies

All individuals newly diagnosed with colorectal cancer or endometrial cancer should undergo universal tumor screening with immunohistochemistry (IHC) for mismatch repair (MMR) proteins or microsatellite instability (MSI) testing to identify Lynch syndrome, regardless of age or family history. 1, 2, 3, 4

Diagnostic Approach

Universal Tumor Screening (Primary Strategy)

The most effective diagnostic strategy is universal screening of all CRC and endometrial cancers, which provides 100% sensitivity and 93% specificity for identifying Lynch syndrome 4. This approach has replaced older family history-based criteria (Amsterdam II, Bethesda) which miss a substantial proportion of cases due to low sensitivity 4.

Testing Algorithm:

1. Initial tumor testing: Perform IHC for MLH1, MSH2, MSH6, and PMS2 proteins on all newly diagnosed CRC or endometrial cancer tissue 1, 3

2. If MLH1 loss detected: Proceed with second-step testing for BRAF V600E mutation or MLH1 promoter hypermethylation 1

   • If BRAF mutation or hypermethylation present: Likely sporadic cancer (not Lynch syndrome)
   • If both negative: Proceed to germline genetic testing

3. If MSH2, MSH6, or PMS2 loss detected: Proceed directly to germline genetic testing 1

4. Germline testing: Test for mutations in the corresponding MMR gene (MLH1, MSH2, MSH6, PMS2) plus EPCAM deletions 2

Important caveat: Second-step testing (BRAF/methylation) may miss up to 10% of Lynch syndrome cases, as these markers occasionally occur in true Lynch syndrome 1. However, this approach is conditionally recommended to reduce cost and anxiety from germline testing in the majority who have sporadic cancers.

Alternative Identification Criteria

For individuals without cancer diagnosis, consider genetic counseling and testing if:

• PREMM1, 2, 6 score ≥5% 2
• First-degree relative with confirmed Lynch syndrome mutation 2
• Strong family history meeting Amsterdam II criteria (though this misses many cases) 5, 4

Surveillance Recommendations

Colonoscopy Surveillance

The AGA strongly recommends surveillance colonoscopy in confirmed Lynch syndrome carriers, which reduces colorectal cancer incidence by 77% (OR 0.23) and mortality by 94% (OR 0.06), extending life expectancy by 7 years. 1

Gene-Specific Colonoscopy Protocol:

• MLH1 and MSH2 carriers:

  • Start at age 20-25 years (or 2-5 years before youngest family diagnosis, whichever is first) 1, 2, 5, 6
  • Repeat every 1-2 years 1, 3

• MSH6 and PMS2 carriers:

  • Start at age 30-35 years 2, 5, 6
  • Repeat every 1-2 years 3

Rationale for gene-specific timing: MSH6 and PMS2 carriers have substantially lower early cancer risk (10-22% by age 70) compared to MLH1/MSH2 carriers (40-80% by age 70) 2. CRC risk before age 40 is <2% for MSH6/PMS2 versus >4% for MLH1/MSH2 7.

Technical requirements: Use high-definition white light endoscopy performed by endoscopists meeting quality standards (adequate caecal intubation and adenoma detection rates) 3, 6. Chromoendoscopy may provide additional benefit but is not mandatory 3, 6.

Gynecologic Surveillance (Women Only)

For endometrial and ovarian cancer prevention:

• Surveillance option: Annual transvaginal ultrasound and endometrial biopsy starting at age 30-35 years 8, 5

  • Evidence for effectiveness is limited 5
  • Adherence improves when mutation status is confirmed 8

• Risk-reducing surgery (preferred after childbearing): Hysterectomy with bilateral salpingo-oophorectomy 8

  • Eliminates endometrial cancer risk (16-60% lifetime risk) 2
  • Reduces ovarian cancer risk (8-10% lifetime risk) 2
  • One study showed zero cancers in women who underwent surgery versus 33% developing endometrial cancer in those who declined 8
  • Consider timing after age 45-50 for MLH1/MSH2 carriers, potentially later for PMS2 carriers 7, 9

Other Cancer Surveillance

Gastric/small bowel/pancreatic surveillance: Not routinely recommended outside clinical trials due to insufficient evidence 3. Consider only in families with documented history of these cancers 2.

Urological surveillance: Not routinely recommended; consider only in high-risk families with documented urological cancers 2.

Chemoprevention

Aspirin for Cancer Prevention

The AGA conditionally recommends offering aspirin 600 mg daily for cancer prevention in Lynch syndrome patients. 1

• One high-quality RCT showed aspirin reduced colorectal cancer incidence by 44% (IRR 0.56) beyond colonoscopy surveillance alone 1
• Treatment duration was up to 4 years in the trial 1
• Adverse risks (1% GI bleeding, <1% stroke) were not statistically significant 1
• Optimal dose and duration remain uncertain; the 600 mg dose tested is high 1
• Individual risk-benefit assessment required 1

Hormonal interventions: Oral contraceptives and progestin-based therapies may reduce endometrial cancer risk by up to 50% in women 9

Cascade Testing for Family Members

Once Lynch syndrome is confirmed, offer genetic testing to all first-degree relatives (parents, siblings, children) for the known familial mutation 2, 10.

• Approximately 50% of relatives receive counseling, and 95% of those counseled choose testing 8
• Cascade testing reduces CRC incidence by 61% and mortality by 78.5% in at-risk relatives 10
• Relatives testing positive follow the same surveillance protocols above
• Relatives testing negative for the familial mutation follow average-risk screening guidelines 2

Common Pitfalls

1. Relying solely on family history criteria: Amsterdam II and Bethesda criteria miss substantial numbers of Lynch syndrome cases due to low sensitivity 4. Universal tumor screening is superior.

2. Assuming BRAF/methylation testing is 100% specific: These markers occasionally occur in true Lynch syndrome, potentially missing up to 10% of cases 1.

3. Using same surveillance timing for all genes: MSH6 and PMS2 carriers have lower early cancer risk and can safely delay colonoscopy initiation to age 30-35 2, 6, 7.

4. Inadequate bowel preparation or incomplete colonoscopy: Repeat within 3 months if preparation is inadequate or examination incomplete 3.

5. Absent MSH6 in rectal tumors after neoadjuvant therapy: May be treatment effect rather than Lynch syndrome 2.

6. Failing to pursue cascade testing: This represents a major missed opportunity, as relatives benefit substantially from identification and surveillance 10.